WallStSmart

Legend Biotech Corp (LEGN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 5674% more annual revenue ($65.77B vs $1.14B). MRK leads profitability with a 13.6% profit margin vs -22.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

LEGN

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -0.24

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LEGN.

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$119.60

$38.64 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LEGN1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
56.5%10/10

Revenue surging 56.5% year-over-year

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

LEGN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-25.9%2/10

ROE of -25.9% — below average capital efficiency

Free Cash FlowQuality
$-111.33M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LEGN

The strongest argument for LEGN centers on Revenue Growth. Revenue growth of 56.5% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : LEGN

The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

LEGN profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

LEGN carries more volatility with a beta of 0.35 — expect wider price swings.

LEGN is growing revenue faster at 56.5% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Legend Biotech Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?